NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free APTO Stock Alerts $1.16 -0.06 (-4.92%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.15▼$1.2450-Day Range$1.16▼$1.9552-Week Range$1.15▼$8.70Volume47,086 shsAverage Volume87,161 shsMarket Capitalization$18.24 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aptose Biosciences alerts: Email Address Aptose Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,606.9% Upside$19.80 Price TargetShort InterestHealthy0.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.31) to ($3.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector425th out of 908 stocksBiological Products, Except Diagnostic Industry65th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAptose Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.59% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently decreased by 35.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 2.8 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aptose Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows14 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.53% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.62% of the stock of Aptose Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to grow in the coming year, from ($3.31) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Aptose Biosciences Stock (NASDAQ:APTO)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesApril 17, 2024 | americanbankingnews.comAptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from AnalystsMarch 29, 2024 | investing.comAptose Biosciences target cut, maintains buy rating on new drug developmentApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 28, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 27, 2024 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | benzinga.comRecap: Aptose Biosciences Q4 EarningsMarch 26, 2024 | globenewswire.comAptose Reports Results for the Fourth Quarter and Full Year 2023April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 18, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024January 29, 2024 | finance.yahoo.comThis Aptose Biosciences Insider Increased Their Holding In The Last YearJanuary 26, 2024 | marketwatch.comAptose Biosciences Shares Drop 11% After Private, Public OfferingsJanuary 26, 2024 | markets.businessinsider.comAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With HanmiJanuary 26, 2024 | finance.yahoo.comAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalJanuary 26, 2024 | investorplace.comWhy Is Aptose Biosciences (APTO) Stock Down Today?December 21, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO), Guidance and ForecastDecember 5, 2023 | morningstar.comAptose Biosciences Inc APTODecember 4, 2023 | msn.comAptose Biosciences files to sell ordinary shares, warrantsDecember 1, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 12, 2023 | seekingalpha.comAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning CallsNovember 10, 2023 | benzinga.comAptose Biosciences: Q3 Earnings InsightsNovember 10, 2023 | markets.businessinsider.comPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph PantginisNovember 9, 2023 | msn.comAptose Biosciences GAAP EPS of -$1.76 beats by $0.22November 1, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)November 1, 2023 | markets.businessinsider.comPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy RatingOctober 30, 2023 | finance.yahoo.comAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibSee More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$38.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,606.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($7.7189) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-458.70% Return on Assets-205.30% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio0.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-6.11Miscellaneous Outstanding Shares15,720,000Free Float14,220,000Market Cap$18.24 million OptionableNo Data Beta1.29 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsPharmaCyte BiotechNASDAQ:PMCBAIM ImmunoTechNYSE:AIMEvaxion Biotech A/SNASDAQ:EVAXZIVO BioscienceNASDAQ:ZIVONanoString TechnologiesNASDAQ:NSTGQView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 12,448 shares on 2/8/2024Ownership: 0.157%Sigma Planning CorpSold 70,309 shares on 2/1/2024Ownership: 0.951%Bernd R SeizingerBought 17,000 shares on 9/22/2023Total: $53,380.00 ($3.14/share)View All Insider TransactionsView All Institutional Transactions APTO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price target for 2024? 5 brokers have issued twelve-month price objectives for Aptose Biosciences' shares. Their APTO share price targets range from $5.00 to $38.00. On average, they predict the company's share price to reach $19.80 in the next year. This suggests a possible upside of 1,606.9% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2024? Aptose Biosciences' stock was trading at $2.54 at the start of the year. Since then, APTO stock has decreased by 54.3% and is now trading at $1.16. View the best growth stocks for 2024 here. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 54,900 shares, a drop of 35.9% from the March 31st total of 85,600 shares. Based on an average daily volume of 93,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.6% of the company's shares are short sold. View Aptose Biosciences' Short Interest. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our APTO earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) issued its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($1.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.48) by $0.04. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APTO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
